Synlogic Inc (SYBX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Synlogic Inc (SYBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8116
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Synlogic Inc (Synlogic), formerly TMC Therapeutics Inc is a clinical stage drug development company that develops novel class of living medicines for the treatment of rare and genetic metabolic diseases, by applying synthetic biology to probiotics. The company’s pipeline includes SYNB1020 a drug candidate used for the treatment of Urea cycle disorder and another candidate SYNB1618 to treat the Phenylketonuria. It also produces drugs based on its proprietary synthetic biology and microbiome platform for the treatment of diseases, including liver disease, inflammatory and immune disorders, and cancer. Its synthetic biotics are designed to make therapeutic effects throughout the body from an initial stage in the microbiome. The company works in partnership with pharmaceutical and biotechnology companies for novel drug development in major disease areas. Synlogic is headquartered in Cambridge, Massachusetts, the US.

Synlogic Inc (SYBX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synlogic Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Synlogic Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Synlogic Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Synlogic Raises USD42 Million in Series C Financing 11
Synlogic Raises USD40 Million in Series B Venture Financing 13
Synlogic Raises USD17 Million Financing 15
Synlogic Raises Funds through Venture Financing 16
Synlogic Raises Additional USD5 Million in Series A Venture Financing 17
Synlogic Raises USD29.4 Million in Series A Venture Financing 18
Partnerships 19
Synlogic Enters into Partnership Agreement with Ginkgo BioWorks 19
Synlogic Enters into R&D Agreement with AbbVie 20
Synlogic Enters into R&D Agreement with Pharmaceutical Company 21
Merger 22
Synlogic and Mirna Therapeutics Merges in Reverse Merger Transaction 22
Equity Offering 24
Synlogic Plans to Raise up to USD200 Million in Public Offering of Securities 24
Synlogic Raises USD30 Million in Public Offering of Shares 25
Synlogic Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD57.5 Million 27
Synlogic Inc – Key Competitors 29
Synlogic Inc – Key Employees 30
Synlogic Inc – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Aug 08, 2018: Synlogic reports second quarter 2018 financial results and provides program updates 32
May 15, 2018: Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update 34
Mar 20, 2018: Synlogic Reports Fourth Quarter and Full Year 2017 Financial Results 35
Nov 13, 2017: Synlogic Reports Third Quarter 2017 Financial Results and Recent Progress 37
Corporate Communications 39
Oct 02, 2018: Synlogic names Dr. Aoife Brennan as President and Chief Executive Officer 39
Oct 02, 2018: Synlogic names Dr. Aoife Brennan as President and Chief Executive Officer 40
May 10, 2018: Synlogic Announces Leadership Change 41
Oct 10, 2017: Synlogic Strengthens Leadership Team with Appointment of Chief Operating Officer and Chief Human Resources Officer 42
Product News 43
04/18/2018: Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of Phenylketonuria 43
Product Approvals 44
Oct 24, 2017: Synlogic Receives Orphan Drug Designation for SYNB1618, a Synthetic Biotic Medicine for the Treatment of Phenylketonuria 44
Jun 26, 2017: Synlogic Receives Fast Track Designation in U.S. for Lead Candidate, SYNB1020 45
Clinical Trials 46
Mar 12, 2018: Synlogic Presents Preclinical Data on Synthetic Biotic Medicine SYNB1618 at Annual Meeting of The Society for Inherited Metabolic Disorders 46
Jan 05, 2018: Synlogic Provides Update on its Phenylketonuria Drug candidate SYNB1618 47
Jun 19, 2017: Synlogic Doses First Subject in Phase 1 Trial of Novel Class of Synthetic Biotic Medicines 48
Mar 22, 2017: Synlogic to Present at 2017 American College of Medical Genetics and Genomics Annual Meeting 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Synlogic Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synlogic Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synlogic Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Synlogic Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Synlogic Raises USD42 Million in Series C Financing 11
Synlogic Raises USD40 Million in Series B Venture Financing 13
Synlogic Raises USD17 Million Financing 15
Synlogic Raises Funds through Venture Financing 16
Synlogic Raises Additional USD5 Million in Series A Venture Financing 17
Synlogic Raises USD29.4 Million in Series A Venture Financing 18
Synlogic Enters into Partnership Agreement with Ginkgo BioWorks 19
Synlogic Enters into R&D Agreement with AbbVie 20
Synlogic Enters into R&D Agreement with Pharmaceutical Company 21
Synlogic and Mirna Therapeutics Merges in Reverse Merger Transaction 22
Synlogic Plans to Raise up to USD200 Million in Public Offering of Securities 24
Synlogic Raises USD30 Million in Public Offering of Shares 25
Synlogic Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD57.5 Million 27
Synlogic Inc, Key Competitors 29
Synlogic Inc, Key Employees 30

List of Figures
Synlogic Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synlogic Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synlogic Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Synlogic Inc (SYBX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nutra Pharma Corp (NPHC):製薬・医療:M&Aディール及び事業提携情報
    Summary Nutra Pharma Corp (Nutra Pharma) acquires, licenses and commercializes pharmaceutical products, technologies, homeopathic drugs and ethical drugs for managing cancer, neurological disorders, autoimmune and infectious diseases, including human Immunodeficiency virus (HIV), multiple sclerosis …
  • CME Group Inc:企業の戦略・SWOT・財務情報
    CME Group Inc - Strategy, SWOT and Corporate Finance Report Summary CME Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Coriolis Telecom SAS:企業の戦略的SWOT分析
    Coriolis Telecom SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Genera Biosystems Ltd (GBI):企業の製品パイプライン分析2018
    Summary Genera Biosystems Ltd (GBL) is a multiplexed molecular diagnostic testing product developer. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is …
  • Reliance Industries Limited:企業の戦略・SWOT・財務分析
    Reliance Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Reliance Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Polenergia SA (PEP):企業の財務・戦略的SWOT分析
    Polenergia SA (PEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • The British United Provident Association Ltd:企業の戦略的SWOT分析
    The British United Provident Association Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Lincoln Pharmaceuticals Ltd (LINCOLN):企業の財務・戦略的SWOT分析
    Lincoln Pharmaceuticals Ltd (LINCOLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Orange Polska S.A.:戦略・SWOT・企業財務分析
    Orange Polska S.A. - Strategy, SWOT and Corporate Finance Report Summary Orange Polska S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Arkle Resources Plc:企業の戦略・SWOT・財務分析
    Arkle Resources Plc - Strategy, SWOT and Corporate Finance Report Summary Arkle Resources Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Iovance Biotherapeutics Inc (IOVA):企業の財務・戦略的SWOT分析
    Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Eisai Inc:企業のM&A・事業提携・投資動向
    Eisai Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eisai Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • GlaxoSmithKline Plc (GSK)-製薬・医療分野:企業M&A・提携分析
    Summary GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respira …
  • Ethypharm SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Ethypharm SA (Ethypharm), a subsidiary of Astorg Partners is a pharmaceutical company that develops and manufactures drugs for the treatment of pain, gastrointestinal, cancer, cardiovascular and central nervous system diseases. The company provides products such as ibuprofen, paracetamol, pr …
  • Euroclear Plc
    Euroclear Plc - Strategy, SWOT and Corporate Finance Report Summary Euroclear Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Sally Beauty Holdings, Inc.:企業の戦略・SWOT・財務情報
    Sally Beauty Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sally Beauty Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Aitken Spence Hotel Holdings PLC:企業の戦略・SWOT・財務情報
    Aitken Spence Hotel Holdings PLC - Strategy, SWOT and Corporate Finance Report Summary Aitken Spence Hotel Holdings PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Lincoln Pharmaceuticals Ltd (LINCOLN):製薬・医療:M&Aディール及び事業提携情報
    Summary Lincoln Pharmaceuticals Ltd (Lincoln Pharmaceuticals) manufactures, markets and exports pharmaceutical products. The company provides pharmaceuticals for cardiovascular, central nervous system, dermatology and ear nose throat disorders; gastrointestinal and genitourinary infections; hematolo …
  • FirstCaribbean International Bank Limited:企業の戦略的SWOT分析
    FirstCaribbean International Bank Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Mercury Systems, Inc.:企業のM&A・事業提携・投資動向
    Mercury Systems, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mercury Systems, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆